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Objectives
To compare salvage robot-assisted laparoscopic prostatectomy
(RALP) outcomes in patients who underwent radiation and
those who underwent focal ablation as primary therapies.
Patients and Methods
We evaluated 126 patients who underwent salvage
RALPbetween 2008 and 2018. Of these, 94 (74.6%) received
radiation and 32 focal ablation (25.4%) as primary therapy.
These groups were compared with regard to clinical,
oncological and functional outcomes. Kaplan–Meier curves
and regression models were used to identify survival
estimations and their predictors.
Results
Before surgery, more patients were potent in the focal
ablation group compared to the radiation group (46.9% vs
22.6%; P = 0.013). Peri-operative characteristics and
complication rates were not significantly different between the
two groups. Postoperative catheterization duration was
shorter in the focal ablation group (mean 10 vs 16 days; P =
0.018). At final pathology, the focal ablation group had higher
non-organ-confined disease (71% vs 50%; P = 0.042) and
positive surgical margin (PSM) rates (43.8% vs 17%; P =
0.004) as compared to the radiation group; however, 5-year
biochemical recurrence (BCR)-free survival rates were similar
(59% vs 56%; P = 0.761). Postoperative 1-year full (no pads/
day) and social (0–1 pad/day) continence rates were
significantly higher in the focal ablation as compared to the
radiation group (77.3% vs 39.2%, P = 0.002, and 87.5% vs
51.3%, P = 0.002, respectively). Multivariate analyses showed
primary focal ablation and nerve-sparing to be predictors of
postoperative continence. Erectile function was preserved in
13% and 27% of preoperatively potent patients in the
radiation and focal ablation groups, respectively (P = 0.435).
No predictors were identified for postoperative potency.
Conclusions
Radiation was associated with inferior functional outcomes
after salvage RALP. Focal therapies were associated with
higher non-organ-confined disease and PSMrates, with no
significant difference in short-term BCR-free survival.
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Introduction
Primary treatment of prostate cancer varies from surgery to
less invasive treatments, including external beam radiation
therapy (EBRT), brachytherapy, high-intensity focused
ultrasonography (HIFU) and cryotherapy. In the USA, 12.7%,
41.5% and 45.8% of men diagnosed with localized prostate
cancer between 2010 and 2015 received active surveillance,
radiotherapy and surgery as initial management, respectively
[1]. Although non-surgical therapies seem attractive to many
patients, 22–69% of men who receive radiotherapy experience
biochemical recurrence (BCR) during follow-up [2,3] and 5–
83% of men require further treatment for local recurrence
after focal therapy [4,5].
Options for salvage treatment for local failure include radical
prostatectomy (RP), cryotherapy, HIFU, brachytherapy and
androgen deprivation. Among them, salvage RP provides high
long-term cancer control rates (77.5% overall and 88.6%
cancer-specific survival at 10 years) [6]. However, salvage RP
is underutilized (< 3% of men with local recurrence undergo
salvage RP) because of inherent technical challenges and high
complication rates [7]. Salvage robot-assisted laparoscopic
prostatectomy (RALP) has emerged as a minimally invasive
alternative to open salvage RP that is associated with less
peri-operative morbidity and equivalent oncological outcomes
[8,9]. It has been considered that all salvage RALP cases are
the same and that patients have been consented in a similar
way, however, over the course of our experience we have
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realized that surgical outcomes can be significantly affected by
the type of primary prostate cancer therapy. Because of the
scarcity of literature directly comparing salvage RALP
outcomes depending on different primary therapies, we
decided to investigate the differences in clinical and
oncological outcomes between post-primary radiation and
focal ablation therapies by examining our series of patients
who underwent salvage RALP.
Patients and Methods
We reviewed our institutional review board-approved
database that includes >11 500 RALP cases performed by a
single surgeon (V.P.). Data were prospectively collected and
retrospectively analysed. From this group, we identified 135
patients who underwent salvage RALP between 2008 and
2018 for failed primary treatment. Of these, nine had missing
data and were excluded. Overall, the study included 126
patients, of whom 94 (74.6%) and 32 (25.4%) had received
radiation and focal ablation treatments, respectively. The
radiation group included EBRT (n = 39), intensity-modulated
radiation (n = 15), proton beam radiation (n = 3),
brachytherapy (n = 23), and combined EBRT and
brachytherapy (n = 14). The focal ablation group included
patients with focal lesion or partial gland ablation using
HIFU (n = 9), cryoablation (n = 20) and other
(electroporation, microwave, n = 3) therapies. All patients
had biopsy-proven local recurrence without evidence of
metastatic prostate cancer.
Surgical Technique
All salvage RALP cases were performed using a
transperitoneal six-port technique, as described by our group
previously [10]. Bilateral retrograde, athermal nerve-sparing
[11] was performed whenever oncologically and technically
feasible and if the patient had some degree of preoperative
sexual function (Sexual Health Inventory for Men [SHIIM]
score >12). The quality of neurovascular bundle (NVB)
preservation was graded by the surgeon on each side using a
five-point scoring system (1: 0%; 2: <50%; 3: 50%; 4: 75%;
and 5: ≥95%), which takes the landmark prostatic/capsular
artery as the anatomical reference [12]. A modified posterior
rhabdosphincteric reconstruction was performed after
prostatectomy [13], followed by vesico-urethral anastomosis
using a modified van Velthoven technique. Pelvic
lymphadenectomy was performed as previously described
[14].
Postoperative Follow-up
We obtained cystograms within 10 days of surgery. The
catheter was removed if no contrast extravasation was seen,
otherwise it was kept until the next imaging obtained 1 week
later. Postoperative complications were documented and
classified according to the modified Clavien–Dindo system
[15].
Patients were followed with PSA, SHIM score and AUA
symptom score questionnaires at 6 weeks, then at 3, 6, 9, 12, 18
and 24 months after surgery. Patient-reported outcomes were
obtained by chart review or telephone survey of all patients at
the time of analysis. BCR was defined as PSA ≥0.2 ng/mL after
salvage RALP. Full continence was defined as use of no pads
and social continence was defined as use of 0–1 pad/day.
Potency was defined as the ability to achieve and maintain
satisfactory erections firm enough for sexual intercourse, with
or without the use of phosphodiesterase-5 inhibitors [16].
Statistical Analysis
Continuous variables were reported as mean  SD or median
and range values. Categorical variables were reported as
frequencies and proportions.
The data on overall NVB preservation were calculated using
the mean of both side’s nerve-sparing percentage, and
categorized into two groups: ‘good’ (>50% of total) and ‘poor’
(≤50% of total) nerve-sparing [17]. We compared the
differences in outcomes between radiation and focal ablation
groups using Student’s t-test, chi-squared and Fisher’s exact
tests, as appropriate. Kaplan–Meier curves and regression
models were used to identify survival estimations and
predictors of postoperative complications, biochemical failure,
continence, and potency. A point-biserial correlation test was
used to determine the relationship between continuous and
categorical variables. Statistical analyses were performed using
SPSSv25 (IBM Corp., Armonk, NY, USA). A two-tailed test
with P value < 0.05 was considered statistically significant.
Results
Baseline Patient Characteristics
Mean age, body mass index and Charlson comorbidity score
were not different between the radiation and focal ablation
groups (Table 1). Preoperatively, LUTS bother scores were
similar between the two groups and 9.7% patients in the
radiation and 9.4% patients in the focal ablation group
reported severe LUTS (Table 1); however, no patients
reported using pads for LUTS or urinary incontinence.
Patients in the focal ablation group had significantly better
erectile function before surgery. The percentage of patients
with SHIM score ≥21 was 46.9% in the focal ablation vs
22.6% in the radiation group (P = 0.007 [Table 1]).
The time between primary prostate cancer treatment and
salvage RALP was significantly longer in the radiation group
(82.2  51.1 vs 61.1  30.2 months; P = 0.039 [Table 1]).
Preoperative cancer characteristics also showed differences
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between the two groups, with the focal ablation group
including more D’Amico intermediate-risk patients and
Gleason 7 disease, and the radiation group having more high-
risk patients and Gleason ≥8 disease (Table 1).
Operative Characteristics and Postoperative
Outcomes
All cases were completed with robotic assistance. There were
no differences in mean operating time, console time,
estimated blood loss, and degree of nerve-sparing between the
two groups (Table 2). Good nerve-sparing was performed in
43% of patients in the radiation group and 34% patients in
the focal ablation group. Peri-operative outcomes with respect
to treatment subtypes are presented in Table S1.
There were no intra-operative complications and no rectal
injuries. Overall, postoperative complications were
encountered in 27 patients (21.4%). Most of these
complications were minor grade (Clavien grades I and II
[Table 2]) and included UTI (6.9%) and urinary retention
after catheter removal (7.8%). Cystographic leak rates within
10 and 20 days after salvage RALP tended to be higher in the
radiation as compared to the focal ablation group (26% vs
15% in the first and 14% vs 6% in the subsequent imaging,
respectively); however, these differences did not reach
statistical significance (P > 0.05 [Table 2]). The mean
postoperative catheterization time was significantly longer in
the radiation group (16 vs 10 days; P = 0.018 [Table 2]).
Postoperative 30-day readmission rates were not significantly
different between the two groups (6.4% vs 3.1%; P = 0.678).
On multivariable analysis (Table 3), previous androgen
deprivation therapy (ADT) was related to an increased risk of
postoperative complications, nearing statistical significance
(odds ratio 2.670 [CI 0.981–7.269]; P = 0.055).
Histopathological Characteristics and Oncological
Outcomes
Pathological outcomes with respect to study groups and
treatment subtypes are presented in Tables 4 and S2,
Table 1 Comparison of clinical demographics and preoperative cancer
characteristics between post-radiation and post-focal ablation groups
treated with salvage robot-assisted laparoscopic prostatectomy.
Characteristic Radiation
group, n = 94
Focal
ablation
group, n = 32
P
Age, years 65.36  6.53 66.16  6.61 0.555
BMI 29.04  4.03 28.47  4.84 0.514
Charlson comorbidity
score
2.66  1.26 2.66  1.23 0.99
Preoperative sexual function, n (%)
No ED (SHIM ≥ 21) 21 (22.6) 15 (46.9) 0.007*
Mild ED (SHIM score
17–20)
17 (18.3) 3 (9.4)
Mild-moderate ED
(SHIM score 12–16)
16 (17.2) 0 (0)
Moderate ED (SHIM
score 8–11)
11 (11.8) 1 (3.1)
Severe ED (SHIM
score 0–7)
28 (30.1) 13 (40.6)
Preoperative AUA symptom score, n (%)
Mild LUTS (score 0–7) 43 (46.2) 16 (50) 0.933
Moderate LUTS
(score 8–19)
41 (44.1) 13 (40.6)
Severe LUTS (score
20–35)
9 (9.7) 3 (9.4)
First treatment to salvage
RALP, months




24 (25.5%) 4 (12.5%) 0.147
Preoperative PSA
(mean  SD)
4.53  3.28 5.77  10.47 0.314
Clinical stage, n (%)
≤cT2c 91 (96.8) 31 (96.8) 0.194
cT3a 3 (3.2) 0 (0)
cT3b 0 (0) 0 (0)
cT4 0 (0) 1 (3.2)
Biopsy Gleason score, n (%)
Gleason score 6 18 (19.1) 6 (18.8) 0.012*
Gleason score 7 31 (33) 20 (62.5)
Gleason score ≥8 36 (38.3) 6 (18.8)
Deferred 9 (9.6) 0 (0)
D'Amico class, n (%)
Low risk 24 (25.8) 4 (12.5) 0.006*
Intermediate risk 31 (33.3) 21 (65.6)
High risk 38 (40.9) 7 (21.9)
ADT, androgen deprivation therapy; BMI, body mass index; ED, erectile dysfunction;
RALP, robot-assisted laparoscopic prostatectomy; SHIM, Sexual Health Inventory for
Men. Values are mean  SD, unless otherwise indicated. *P < 0.05.
Table 2 Comparison of peri-operative outcomes and complication rates






group, n = 32
P
Total operating time, min 128.95  19.33 122.38  16.26 0.087
Total console time, min 83.94  11.38 84.06  12.4 0.958
Estimated blood loss, mL 106.65  60.48 92.5  56.09 0.247
Nerve-sparing degree, n (%)
Poor nerve-sparing
(≤50% of total)
53 (56.4) 21 (65.6) 0.410
Good nerve-sparing
(>50% of total)
41 (43.6) 11 (34.4)
Hospital stay, days 1.37  1.44 1.09  0.53 0.289
Postoperative catheter time, days 16.14  13.95 10.16  3.7 0.018*
Cystographic leak, n (%)
Leak at 10 days 25 (26.6) 5 (15.6) 0.239
Leak at 20 days 14 (14.9) 2 (6.2) 0.355
Postoperative complications, n (%)
None 69 (74.2) 29 (90.6) 0.446
Clavien I 9 (9.7) 1 (3.1)
Clavien II 11 (11.8) 1 (3.1)
Clavien IIIa 2 (2.2) 1 (3.1)
Clavien IIIb 1 (1.1) 0 (0)
Clavien IVa 1 (1.1) 0 (0)
Clavien V 0 (0) 0 (0)
Postoperative 30-day
readmission, n (%)
6 (6.4) 1 (3.1) 0.678
Values are mean  SD, unless otherwise indicated. *P < 0.05.
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respectively. The pathological Gleason score 7 rate was
significantly higher in the focal ablation group and Gleason
score ≥8 was significantly higher in the radiation group
(Table 4). The proportion of patients with pathologically
non-organ-confined disease (≥pT3) was 71% in the focal
ablation vs 50% in the radiation group (P = 0.042). There was
a significantly higher positive surgical margin (PSM) rate in
the focal ablation group (43.8% vs 17%, respectively; P =
0.004 [Table 4]). In both groups, the rate of good nerve-
sparing was not significantly different between patients who
did and did not have PSMs (Table 4); however, the incidence
of extraprostatic extension (EPE) was significantly higher in
patients with PSMs than in patients without (P < 0.001 for
radiation group and P = 0.015 for focal ablation group
[Table 4]).
In the whole cohort, there was no correlation between the
time from primary treatment until salvage surgery and the
presence of EPE or PSMs (data not shown). When data were
examined with respect to each study group, time to salvage
RALP was significantly shorter in patients with EPE in the
focal ablation group (54  30.6 vs 81.3  21.3 months; P =
0.03 [Table 4]) with a significant negative correlation between
time and EPE (rpb = 0.411, P = 0.03). In the radiation
group, time to salvage RALP was significantly longer in
patients with PSMs (110.7  47.7 vs 75.5  49.9 months; P =
0.01 [Table 4]), with a statistically significant positive
correlation (rpb = 0.271, P = 0.016).
Eighteen and twelve percent of patients in the radiation and
focal ablation groups had postoperative PSA persistence
(≥0.2 ng/mL), respectively. During follow-up, 17% of patients
in the radiation and 18.8% of patients in the focal ablation
group developed BCR (Table 4). The 5-year estimated BCR-
free survival rates were 56% and 59% in the radiation and
focal ablation groups, respectively (P = 0.761 [Fig. 1]). In
multivariable analysis, only Gleason score ≥8 at pathology
was predictive of biochemical failure (Table 3).
Functional Outcomes
Overall full (no pads) and social (0–1 pad/day) continence
rates at 1 year were 77.3% vs 39.2% (P = 0.002) and 87.5% vs
51.3% (P = 0.002), respectively, for the focal ablation and
radiation groups. In patients who were continent
preoperatively, 47.9% in the radiation group had severe loss
of continence (≥3 pad use/day) at the last postoperative
follow-up as compared to 9.4% patients in the focal ablation
group (P = 0.001 [Table 4]). Kaplan–Meier analysis reporting
the probability of postoperative continence showed
significantly higher and faster recovery in the focal ablation
group (P = 0.001 [Fig. 2]). In multivariable analysis, focal
ablation therapy and good nerve-sparing were predictive of
full continence recovery (Table 3).
In patients with no or mild erectile dysfunction (SHIM score
≥17) before surgery, five of 38 patients (13.1%) in the
radiation and five of 18 patients (27.7%) in the focal ablation
group had preserved erectile function at the last postoperative
follow-up (Table 4). Although there was a trend towards
higher postoperative potency probability in the focal ablation
group (Fig. 3), the difference did not reach statistical
significance (P = 0.179). Multivariable analysis did not reveal
any independent predictors for postoperative potency
(Table 3).
Discussion
In the last decade, salvage RALP has emerged as a minimally
invasive alternative for recurrent prostate cancer after primary
non-surgical treatment [8,9]. We previously described our
salvage RALP technique and published our outcomes
[10,14,18]. In the course of our growing experience, we have
noticed differences in clinical presentation and outcomes
Table 3 Multivariable analysis of factors influencing postoperative
complication risk, biochemical failure, continence, and potency after
salvage robot-assisted laparoscopic radical prostatectomy
OR (95% CI) P
Postoperative any complication
Age 1.015 (0.922–1.118) 0.760
BMI, <30 vs ≥30 kg/m2 0.478 (0.170–1.345) 0.162
Charlson comorbidity index 0.679 (0.390–1.181) 0.171
Serum PSA 0.960 (0.833–1.105) 0.568
Clinical stage, ≤cT2b vs ≥cT3a 0.690 (0.113–4.227) 0.688
Primary therapy, ablation vs radiation 3.238 (0.854–12.273) 0.084
Previous adjuvant/salvage ADT 2.670 (0.981–7.269) 0.055*
Biochemical failure
Age 0.97 (0.903–1.042) 0.402
Serum PSA 1.061 (0.951–1.184) 0.292
Primary therapy, radiation vs ablation 1.194 (0.397–3.595) 0.752
Degree of nerve-sparing, ≤50% vs >50% of
total
1.085 (0.429–2.742) 0.863
EPE on pathology 1.722 (0.614–4.832) 0.302
Pathological Gleason score, ≥8 vs <8 4.013 (1.549–10.395) 0.004*
PSM on pathology 2.145 (0.686–6.706) 0.19
Full continence recovery
Age, <65 vs ≥65 years 2.058 (0.834–5.077) 0.117
BMI, <30 vs ≥30 kg/m2 1.413 (0.598–3.337) 0.431
Preoperative AUA symptom score, <8 vs ≥8 1.732 (0.765–3.920) 0.188
Primary therapy, ablation vs radiation 2.601 (1.040–6.507) 0.041*
Previous adjuvant/salvage ADT 0.880 (0.325–2.380) 0.801
Degree of nerve sparing, >50% vs ≤50% of
total
2.467 (0.996–6.108) 0.051*
Cystographic leak at 10 days 0.610 (0.224–1.656) 0.332
Potency recovery
Age, <65 vs ≥65 years 1.308 (0.329–5.206) 0.703
BMI, <30 vs ≥30 kg/m2 1.488 (0.452–4.902) 0.514
Charlson comorbidity index, ≤2 vs >2 3.131 (0.784–12.502) 0.106
Preoperative SHIM score, <21 vs ≥21 0.504 (0.138–1.840) 0.300
Primary therapy, ablation vs radiation 1.151 (0.323–4.103) 0.828
Previous adjuvant/salvage ADT 0.154 (0.018–1.329) 0.089
Degree of nerve-sparing, >50% vs ≤50% of
total
2.006 (0.521–7.722) 0.312
ADT, androgen deprivation therapy; BMI, body mass index; EPE, extraprostatic
extension; OR, odds ratio; PSM, positive surgical margin; SHIM, Sexual Health
Inventory for Men. *P < 0.05.
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between patients who received different primary therapies. In
the present study, we investigated these differences by
analysing our contemporary salvage RALP series which
represents one of the largest salvage prostatectomy series in
the world.
This study included 94 patients (74.6%) with radiation and 32
(25.4%) with focal therapy as the primary treatment. We
noted significant differences in clinical presentation and
pathological characteristics between these two groups. For
example, patients who underwent focal ablation had better
erectile function before surgery. This was an expected finding
as focal therapies aim to spare at least one NVB to preserve
erectile function [19,5].
The time from first treatment to salvage RALP was
significantly shorter in the focal ablation compared to the
radiation group (mean 61 vs 82 months; P = 0.039), and it
was further reduced in patients with EPE in the focal ablation
group. Compared to the radiation group, the focal ablation
group also had a higher incidence of extraprostatic disease
(71% vs 50%; P = 0.042) and PSMs (43% vs 17%; P = 0.004).
The reason for faster recurrence and higher rate of adverse
pathological features after focal therapy is probably
multifactorial. First, inadequate staging before primary
ablation may have led to wrong patient selection for focal
therapy, resulting in prostate cancer persistence or early
recurrence with more aggressive disease. Multiparametric
MRI is used to stage and identify patients for focal therapy
[20]. Despite recent advances in technology, multiparametric
MRI has negative and positive predictive values that range
from 63% to 98% and 34% to 68% for detecting aggressive
prostate tumours, respectively, and presents only moderate
inter-reader reproducibility, currently limiting its use to
experienced centres [20,21].
Second, prostate cancer persistence and/or recurrence after
focal therapy is generally associated with more aggressive
features compared to pre-first-line treatment [22]. In a recent
series of 35 men treated with salvage RALP for post-HIFU
recurrence, Thompson et al. [23] reported upstaging or
upgrading features in 80% of their patients. Furthermore,
prostate cancer recurrences were in the intended field of
treatment in 94% of patients with significant bilateral disease
in 80%. This may be attributable to incomplete tissue necrosis
in the intention-to-treat field, theoretically resulting in the
development of ‘ablation-resistant’ clones that repopulate the
ablated field and metastasize locoregionally [23,24].
Third, patient selection bias for salvage prostatectomy after
post-focal ablation recurrence may have resulted in a higher
incidence of aggressive features in this cohort [25]. Most
recurrences after focal therapy undergo other salvage ablative
therapies and salvage RP is generally reserved for men with
bilateral significant or high-risk disease, or in whom re-ablation
is not technically feasible [23,26]. Thus, our focal ablation
cohort may not be representative of all men experiencing
recurrence after focal therapies. It is difficult to determine
which factor(s) mentioned above played a major role in our
outcomes since all our patients were referred from other
centres and we did not have complete pre-treatment records.
The high post-focal ablation PSM rate (43.8%) in the present
study may raise concerns about the safety of nerve-sparing in
these patients. Other studies reported the feasibility of nerve-
Table 4 Comparison of pathological, oncological and functional
outcomes between post-radiation and post-focal ablation groups
Radiation
group, n = 94
Focal
ablation
group, n = 32
P
Prostate weight, g 44.27  11.85 35.31  15.58 0.001*
Tumour volume, % 18.53  16.71 21.38  16.48 0.407
Pathological stage, n (%)
≤pT2c 47 (50) 9 (29) 0.069
pT3a 21 (22.3) 14 (45.2)
pT3b 26 (27.8) 8 (25.8)
pT4 0 (0) 0 (0)
Nodal stage, n (%)
pN0 76 (80.9) 25 (78.1) 0.714
pN1 10 (10.6) 5 (15.6)
pNx 8 (8.5) 2 (6.2)
Pathological Gleason score, n (%)
6 2 (2.1) 0 (0) 0.011*
7 36 (38.3) 23 (71.9)
≥8 40 (42.6) 6 (18.8)
Deferred 16 (17) 3 (9.4)
EPE, n (%) 47 (50) 22 (71) 0.042*
PSM, n (%) 16 (17) 14 (43.8) 0.004*
EPE in positive vs negative
PSM
16 (100) vs 31
(39.7)*
13 (92.9) vs 9
(52.9)*
Good nerve-sparing in
positive vs negative PSM
6 (37.5) vs 35
(44.8)
5 (35.7) vs 6
(33.2)
First treatment to salvage RALP, months
EPE positive vs negative 88.07  43.21 vs
75.85  58.46




PSM positive vs negative 110.67  47.68
vs 75.52 
49.96*
61.79  33.71 vs
60.48  27.76
Follow-up, months 32  24.21 29.24  26.57 0.592
Cancer status at last follow-up, n (%)
Biochemical recurrence-free 61 (64.9) 22 (68.8) 0.763
Biochemical persistence 17 (18.1) 4 (12.5)
Biochemical recurrence 16 (17) 6 (18.8)
Continence change at last follow-up, n (%)
No continence loss 35 (37.2) 20 (62.5) 0.001*
Mild continence loss
(0–1 pad/day)
8 (8.5) 7 (21.9)
Moderate continence loss
(2 pads/day)
6 (6.4) 2 (6.2)
Severe continence loss
(≥3 pads/day)
45 (47.9) 3 (9.4)
Potency change at last follow-up, n (%)
Patients with good baseline EF (SHIM score 17–25)
EF unchanged 5 (5.3) 5 (15.6) 0.435
EF deteriorated 33 (35.1) 13 (40.6)
Patients with poor baseline EF (SHIM score 0–16)
EF decreased/unchanged 56 (59.5) 14 (43.7)
EF, erectile function; EPE, extraprostatic extension; PSM, positive surgical margin;
RALP, robot-assisted laparoscopic prostatectomy; SHIM, Sexual Health Inventory for
Men. Values are mean  SD, unless otherwise indicated. *P < 0.05.
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sparing during salvage RALP [17,25,27]. Nunes-Silva et al.
[25] performed bilateral nerve-sparing in 54% and unilateral
nerve-sparing in 36% of 22 men treated with salvage RALP
after focal therapy and reported an overall PSM rate of only
4.5%. Marconi et al. [24] performed nerve-sparing in 76% of
their 82 post-ablation salvage RALP patients and reported a
13% overall PSM rate. These lower PSM rates may be related
to the lower incidence of EPE in these studies (between 27%
and 50%) as compared to our study (71%). Extraprostatic
disease was found to be the most important predictor of
PSMs after robot-assisted RP [28] and it was present in
almost all patients with PSMs in the present study. This
underscores the importance of careful preoperative staging
and suggests that patients demonstrating signs of
extraprostatic disease may not be suitable for nerve-sparing
during salvage RALP.
Despite the difference in EPE and PSM rates, estimated
BCR-free survival was not significantly different between the
focal ablation and radiation groups in the present study.
This was in line with a study that compared minimally
invasive salvage RP outcomes after whole-gland vs focal
therapies over a median follow-up of 62 months [27]. The
follow-up in the present study was similarly short, and our
long-term results are awaited to better evaluate the BCR
differences between the post-radiation and focal ablation
groups. We found pathological Gleason score ≥8 to be
predictive of BCR, which was consistent with our previous
data [17].
In the present series, postoperative complication and 30-day
readmission rates were not significantly different between the
radiation and focal ablation groups. Postoperative
complications occurred in 21% of our patients and the
majority of these were low grade (Clavien grades I and II).
The total complication rate in other contemporary salvage
RALP series ranged between 6% and 47%, with a 0–35%
major complication rate [24,25,27,29,30]. Our relatively low
complication rate is probably related to the single-surgeon
characteristic of our series and the great experience of our
surgeon, who has performed >11 500 RALPs.
Interestingly, we found history of previous adjuvant or
salvage ADT to be a potential predictor of postoperative
complications in multivariable analysis (odds ratio 2.67; P =
0.055). Similarly, in a recent multicentre study of 395 patients
who underwent salvage RP, Gontero et al. [29] found a 60%
increased probability of experiencing at least one
postoperative complication in patients with a history of ADT.
They attributed this increased risk to local and systemic
consequences of ADT, which may result in a poorer response
to stress and more difficult surgical recovery. Nevertheless, it




































Fig. 1 Biochemical recurrence (BCR)-free survival after salvage robot-assisted laparoscopic prostatectomy for the post-radiation and post-focal ablation
groups (number of patients in the study groups at each time point is shown at the bottom of the figure).
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is difficult to fully explain the association between previous
ADT and salvage prostatectomy outcomes, and this should be
addressed by further studies.
In the present study, salvage RALP resulted in better
functional outcomes after focal ablation than after radiation
therapies. Postoperative full and social continence rates at
1 year were significantly higher in the focal ablation group.
This may be related to the more extensive peri-urethral tissue
damage after radiation, which is suggested by the higher
postoperative cystographic leak rates and prolonged
catheterization in the radiation group. In other studies,
continence (0–1 pad/day) rates were reported as 39–64% for
salvage RALP after radiation [29–31] and 52–84% after focal
ablation failure [24,25,27], which is consistent with our
results. In a recent report, primary ablation compared to
radiation/brachytherapy showed a positive trend for post-
salvage RP continence preservation with a near statistical
significance (P = 0.06) [29]. This is in line with our
multivariate analysis which confirmed primary focal ablation
treatment as an independent predictor of continence after
salvage RALP.
In patients with preoperative erectile function (SHIM score
≥17), potency was preserved in 13% in the radiation and 27%
in the focal ablation group in the present study. Potency rates
after salvage RALP ranged between 8% and 31.5% in other
studies [24,25,27,29–31]; however, none of these studies
analysed the impact of primary therapy on post-salvage RALP
potency recovery. Although the focal ablation group showed a
higher postoperative potency trend in the present study, the
difference did not reach statistical significance, possibly
because of the small number of potent patients in both
groups.
The present study has several limitations. First, this is a
retrospective study like other salvage RALP series; however,
our institutional review board-approved and prospectively
maintained database ensured the quality of peri-operative
clinical and pathological data. Second, there is in-group
heterogeneity in both study groups and it is difficult to
examine the influence of other possible confounding factors
on our outcomes. Third, our results come from a highly
experienced single surgeon; thus, these outcomes may not be
generalizable to other centres with less experience. Fourth,
our follow-up is not long enough to draw final conclusions
regarding oncological survival differences between radiation
and focal ablation failures. Fifth, we did not have complete
pre-first-line treatment records; therefore, the reasons for
higher incidence of adverse pathological findings at salvage
RALP after focal therapy recurrence could not be elucidated.
Despite these limitations, this study adds to the current







































Fig. 2 Cumulative probability of full continence (no pads/day) after salvage robot-assisted laparoscopic prostatectomy by study group (number of
patients in the study groups at each time point is shown at the bottom of the figure).
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literature by systematically analysing the differences in
outcomes between post-radiation and post-ablation salvage
RALP.
In conclusion, all salvage RALPs are not the same. Patients
who had focal therapy as primary treatment had better
erectile function before surgery than patients who had
radiation. Nerve-sparing can be performed in both settings
depending on technical feasibility and is a predictor for
postoperative continence recovery. However, patients with
signs of extracapsular disease may not be suitable for nerve-
sparing as there is an increased risk of PSMs in this group.
Salvage RALP was associated with inferior functional
outcomes after radiation and higher adverse pathology rates
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